Expansion of Distribution Network for RYPLAZIM

Kedrion Expands Ryplazim Distribution Network for PLGD-1 Patients 

FORT LEE, NJ., Mar. 20, 2025 /PRNewswire/ -- Kedrion Biopharma Inc. expands the distribution network for Ryplazim, a plasma-derived human plasminogen indicated for treating patients with plasminogen deficiency type 1 (PLGD-1). This expansion ensures timely access to this vital medication for patients across the US. PLGD-1 is a serious condition causing abnormal fibrin-rich lesions on mucosal surfaces, potentially leading to severe consequences like vision and hearing loss, airway obstruction, and infertility. Ryplazim, the only FDA approved therapy for PLGD-1 patients, offers an important treatment option. 

The recent FDA approval of the technology transfer and manufacturing capacity expansion of Ryplazim has enabled Kedrion to broaden its limited distribution network due to the increase of supply. This crucial step means more patients can have access to this treatment. The expanded network now includes a new distribution partner and two new specialty pharmacies.

CuraScript SD a provider of comprehensive distribution solutions, joins existing partners FFF Enterprises and The Alliance Pharmacy in distributing Ryplazim to patients with PLGD-1.

CVS Health and Soleo Health have been added to the list of specialty pharmacies carrying Ryplazim, increasing access points for patients. These pharmacies join Nufactor, enhancing the network to ensure wider availability.

This collaborative effort underscores Kedrion's commitment to improving patient care and broadening access to essential therapies. 

To learn more about accessing Ryplazim and its potential benefits, please visit www.Ryplazim.com.

Read the full press release: https://lnkd.in/ez242whw

kendrion_press_release_ryplazim.docx
File Size:	36 kb
File Type:	docx

Download File

---